Аuthors: Dubovyk Ye. I., Garbuzova V. Yu., Prosol D. А., Shimko K. A.
T2255C polymorphism (rs2359612) of vitamin K-epoxidoreductase (VKORC1) gene in 118 patients with acute coronary syndrome (ACS) and in 234 healthy people was determined. It was shown that in patients with ACS interrelation of main homozygotes, heterozygotes and minor homozygotes were 27.1 %, 41.5 % and 31.4 % (in control – 37.2 %, 42.7 %, 20.1 %. P = 0,038 by χ2-test). Thus, there is an association between T2255C polymorphism and the development of ACS: the risk of ACS in homozygotes for the minor allele (C/C) is 2.1 times higher than in homozygous for the major allele.
Key words: vitamin K-epoxidoreductase, allelic polymorphism, acute coronary syndrome.
1. Vitamin K epoxidereductase complex subunit 1 (VKORC1): The key protein of the vitamin K cycle / J. Oldenburg, C. G. Bevans, C. R. Muller [et al.] // Antioxid. Redox Signal. – 2006. – Vol.8 – P. 347–353.
2. Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1) Polymorphism and Aortic Calcification / M. Teichert, L. E. Visser, R. H. N. van Schaik [et al.] // Arterioscler. Thromb. Vasc. Biol. – 2008. – Vol.28. – P. 771–776.
3. Common VKORC1 variants are not associated with arterial or venous thrombosis / A. Hindorff, S. R. Heckbert, N. Smith, K. D. Bennet [et al.] // Journal of Thrombosis and Haemostasis. – 2007. – Vol. 5. – P. 2025–2027.
4. VKORC1 Haplotypes Are Associated With Arterial Vascular Diseases (Stroke, Coronary Heart Disease, and Aortic Dissection / Y. Wang, Z. Weili, Y. Zhang [et al.] // Circulation. – 2006. – Vol. 113. – P. 1615–1621.
5. ACC/AHA guidelinesfor the management of patients with unstable angina and non ST-elevation myocardial infarction: executive summary and recommendations. A report of the american college of cardiology / E. Braunwald, E. M. Antman, N. H. Brooks [et al.]// American Heart Association task force on practice guidelines (committee on management of patients with unstable angina) // Circulation.–2000. – Vol. 102. – P. 1193–1209.
6. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The task force on the management of acute coronary syndromes of the European society of cardiology / M. E. Bertrand, M. L. Simoons, K. A. Fox [et al.] // Eur. Heart J. – 2002. – Vol. 23. – P. 1809–1840.
7. World Health Organization. Nomenclature and criteria for diagnosis of ischemic heart disease // Circulation. – 1979. – Vol. 59. – P. 607–609.
8. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement / D. Wang, H. Chen, K. M. Momary [et al.] // Blood. – 2008. – Vol. 112. – P. 1013–1021.
9. VKORC1 Haplotypes Are Associated With Arterial Vascular Diseases (Stroke, Coronary Heart Disease, and Aortic Dissection / Y. Wang, Z. Weili, Y. Zhang [et al.] // Circulation. – 2006. – Vol. 113. – P. 1615–1621.
10. Lack of association between variants in the VKORC1 gene and cerebrovascular or coronary heart disease / R. Lemmens, S. Abboud, L. Vanhees [et al.] // Thromb. Haemost. – 2008. – Vol. 12. – P. 2220–2223.
11. Common VKORC1 variants are not associated with arterial or venous thrombosis / A. Hindorff, S. R. Heckbert, N. Smith [et al.] // Journal of Thrombosis and Haemostasis. – 2007. – Vol. 5. – P. 2025–2027.
12. VKORC1 genetic polymorphism and risk of venous thromboembolism in postmenopausal women: new findings and meta–analysis / C. Verstuyft, M. Canonico, E. Bouazi [et al.] // J. Thromb. Haemost. – 2009.– Vol. 7. – P. 1034–1036.
13. No clear link between VKORC1 genetic polymorphism and the risk of venous thrombosis or peripheral arterial disease / M. D. Smadja, M. A. Loriot, L. A. Hindorff [et al.] // Thromb. Haemost. – 2008. – Vol. 99. – P. 970–972.
14. Vitamin K epoxide reductase genetic polymorphism is associated with venous thromboembolism: results from the EDITH Study / K. Lacut, C. Larramendy–Gozalo [et al.] // J. Thromb. Haemost. – 2007. – Vol. 5. – P. 2020–2024.